Varipulse, MedTech and Johnson & Johnson

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of cardiac ...
The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...
Multibillion-dollar buyouts returned last year, led by Johnson & Johnson’s $13.1 billion acquisition of Shockwave Medical.